Atrium Therapeutics, Inc. Common Stock (RNA) — Capital Reinvestment Ratio
Latest as of December 2023:
0.05x
Atrium Therapeutics, Inc. Common Stock (RNA) has a Capital Reinvestment Ratio of 0.05x as of December 2023, meaning it reinvests 0% of its operating cash flow ($16.50 Million) in capital expenditures ($863.00K). See RNA FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.05x
Capex / Operating Cash Flow
Operating Cash Flow
$16.50 Million
USD
Capital Expenditures
$863.00K
USD
Data as of
Dec 2023
Most recent filing
Atrium Therapeutics, Inc. Common Stock Capital Reinvestment Ratio (2019–2019)
This chart tracks Atrium Therapeutics, Inc. Common Stock's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Atrium Therapeutics, Inc. Common Stock (2019–2019)
Year-by-year Capital Reinvestment Ratio for Atrium Therapeutics, Inc. Common Stock from 2019 to 2019. For live market cap and broader valuation context, see RNA market cap overview.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2019 | 0.09x | $2.49 Million | $235.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow